Four New Patents Issued, PROCYSBI® Granted Additional U.S. Orphan Exclusivity
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Citi Upgrades Raptor Pharmaceuticals (RPTP) to Buy
January 26, 2016 5:46 PM ESTCiti upgraded Raptor Pharmaceuticals (NASDAQ: RPTP) from Neutral to Buy.
For an analyst ratings summary and ratings history on Raptor Pharmaceuticals click here. For more ratings news on Raptor Pharmaceuticals click here.
Shares of Raptor Pharmaceuticals closed at $3.83 yesterday.
... MoreRaptor Pharma (RPTP) Gains on New PROCYSBI Patents and Orphan Drug Exclusivity Extension
January 25, 2016 10:22 AM ESTRaptor Pharma (NASDAQ: RPTP) is gaining sharply after the company announced this morning that a U.S. PROCYSBI patent, number 9,233,077, is now... More
